ITRM Company Profile and Key Details

Iterum Therapeutics plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.09. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.03 and $1.42. With a market capitalization of about $1.60 million, Iterum Therapeutics plc is classified as a micro-cap and shows higher-than-market volatility (beta ~3.01). Key stats such as the average daily volume over the past year has been around 15.82 million shares, trading with heavier-than-usual volume. Headquartered in Dublin, None, Iterum Therapeutics plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Corey N. Fishman, the company employs approximately 9 people and listed since May 25, 2018. Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.

Iterum Therapeutics plc trades at a P/E ratio of -0.05, slightly below the S&P 500 average, with a price-to-sales ratio of 4.1 and a price-to-book ratio of -0.19 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.08, also below market averages.

ITRM has shown mixed momentum, gaining 0.43% over the past week and -51.15% over the past quarter, though year-to-date performance is down -1.67%. Short-term trend indicators are bullishly aligned (SMA20 -13.98%, SMA50 -25.02%, SMA200 -63.54%). The stock’s 14-day RSI is 37.89 (weak momentum), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.27% below its high and over 20.9% above its low. Average 10-day trading volume of 171.90 million shares is significantly above the 3-month average of 15.71 million, indicating heightened recent market interest.

Iterum Therapeutics plc has 44.66 million shares outstanding. The public float is 44.25 million shares, elevated short interest at 4.95% of float. This equals 2.08 million shares. The short ratio is 2.59 days. Institutional investors hold 8.66% of the float. Insiders own 0.95%. CANAAN X L.P. holds 1.73 million shares, HEALY JAMES has 1.73 million shares and Sofinnova Venture Partners IX, L.P. has 1.23 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Iterum Therapeutics plc generated EPS of -$0.75 over the past year. Five-year average earnings growth is 58.85%. Wall Street analysts project EPS growth of 22.77% annually over the next five years. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.14. Next year's EPS is expected at $14.53. Iterum Therapeutics plc earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 23.08%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include -42.31% in August 14, 2024.

Our AI price prediction model suggests that Iterum Therapeutics plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by April 14, 2026, within a range of $0.00 to $0.03 3-Month Outlook: Projected fall of -66.67%, reaching $0.01 by June 29, 2026, with a range of $0.00 to $0.07. 1-Year Outlook: Projected loss of -66.67%, with price at $0.01 by March 31, 2027, within a range of $0.00 to $0.05.

Iterum Therapeutics plc (NASDAQ:ITRM) shares are flat -1.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Iterum Therapeutics plc trading at a premium to the broader market with a P/E of -0.05. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.36, suggesting 21100.0% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-66.67% over three months), and a longer-term loss (-66.67% over one year), with expected trading ranges indicating moderate volatility.